These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 15690500)

  • 1. Gadodiamide T1 relaxivity in brain tissue in vivo is lower than in saline.
    Pickup S; Wood AK; Kundel HL
    Magn Reson Med; 2005 Jan; 53(1):35-40. PubMed ID: 15690500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gd-DTPA T1 relaxivity in brain tissue obtained by convection-enhanced delivery, magnetic resonance imaging and emission spectroscopy.
    Haar PJ; Broaddus WC; Chen ZJ; Fatouros PP; Gillies GT; Corwin FD
    Phys Med Biol; 2010 Jun; 55(12):3451-65. PubMed ID: 20508321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Treatment With Chelating Agents Depends on the Stability of Administered GBCAs: A Comparative Study in Rats.
    Boyken J; Frenzel T; Lohrke J; Jost G; Schütz G; Pietsch H
    Invest Radiol; 2019 Feb; 54(2):76-82. PubMed ID: 30358694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study.
    Fretellier N; Idée JM; Dencausse A; Karroum O; Guerret S; Poveda N; Jestin G; Factor C; Raynal I; Zamia P; Port M; Corot C
    Invest Radiol; 2011 May; 46(5):292-300. PubMed ID: 21263333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MR characterization of mild hyperthermia-induced gadodiamide release from thermosensitive liposomes in solid tumors.
    Peller M; Schwerdt A; Hossann M; Reinl HM; Wang T; Sourbron S; Ogris M; Lindner LH
    Invest Radiol; 2008 Dec; 43(12):877-92. PubMed ID: 19002060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does Age Interfere With Gadolinium Toxicity and Presence in Brain and Bone Tissues?: A Comparative Gadoterate Versus Gadodiamide Study in Juvenile and Adult Rats.
    Fretellier N; Granottier A; Rasschaert M; Grindel AL; Baudimont F; Robert P; Idée JM; Corot C
    Invest Radiol; 2019 Feb; 54(2):61-71. PubMed ID: 30394964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability and trapping of magnetic resonance imaging contrast agents during high-intensity focused ultrasound ablation therapy.
    Hijnen NM; Elevelt A; Grüll H
    Invest Radiol; 2013 Jul; 48(7):517-24. PubMed ID: 23695082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose contrast-enhanced magnetic resonance imaging of brain metastases at 3.0 T using high-relaxivity contrast agents.
    Huang B; Liang CH; Liu HJ; Wang GY; Zhang SX
    Acta Radiol; 2010 Feb; 51(1):78-84. PubMed ID: 19912078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
    Fries P; Runge VM; Bücker A; Schürholz H; Reith W; Robert P; Jackson C; Lanz T; Schneider G
    Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of Gd-DTPA relaxivity and proton exchange rates in tissue.
    Donahue KM; Burstein D; Manning WJ; Gray ML
    Magn Reson Med; 1994 Jul; 32(1):66-76. PubMed ID: 8084239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging observations of blood-brain-barrier permeability in an animal model of brain injury.
    Ford JC; Wood AK; Van Winkle TJ; Kundel HL
    Acad Radiol; 1997 Feb; 4(2):115-26. PubMed ID: 9061084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
    Sieber MA; Pietsch H; Walter J; Haider W; Frenzel T; Weinmann HJ
    Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moderate Renal Failure Accentuates T1 Signal Enhancement in the Deep Cerebellar Nuclei of Gadodiamide-Treated Rats.
    Rasschaert M; Idée JM; Robert P; Fretellier N; Vives V; Violas X; Ballet S; Corot C
    Invest Radiol; 2017 May; 52(5):255-264. PubMed ID: 28067754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo imaging studies of a new endohedral metallofullerene nanoparticle.
    Fatouros PP; Corwin FD; Chen ZJ; Broaddus WC; Tatum JL; Kettenmann B; Ge Z; Gibson HW; Russ JL; Leonard AP; Duchamp JC; Dorn HC
    Radiology; 2006 Sep; 240(3):756-64. PubMed ID: 16837672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
    Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
    Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadolinium-chitosan nanoparticles as a novel contrast agent for potential use in clinical bowel-targeted MRI: a feasibility study in healthy rats.
    Cheng JJ; Zhu J; Liu XS; He DN; Xu JR; Wu LM; Zhou J; Feng Q
    Acta Radiol; 2012 Oct; 53(8):900-7. PubMed ID: 22919051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of in vivo rat muscle Gd-DTPA relaxivity at 6.3 T.
    Rozijn TH; van der Sanden BP; Heerschap A; Creyghton JH; Boveé WM
    MAGMA; 1999 Oct; 9(1-2):65-71. PubMed ID: 10555175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid.
    Jia J; Puls D; Oswald S; Jedlitschky G; Kühn JP; Weitschies W; Hosten N; Siegmund W; Keiser M
    Invest Radiol; 2014 Feb; 49(2):78-86. PubMed ID: 24056116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization.
    Ogan MD; Schmiedl U; Moseley ME; Grodd W; Paajanen H; Brasch RC
    Invest Radiol; 1987 Aug; 22(8):665-71. PubMed ID: 3667174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide.
    Fretellier N; Idée J; Bruneval P; Guerret S; Daubiné F; Jestin G; Factor C; Poveda N; Dencausse A; Massicot F; Laprévote O; Mandet C; Bouzian N; Port M; Corot C
    Br J Pharmacol; 2012 Feb; 165(4b):1151-62. PubMed ID: 21740412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.